Last reviewed · How we verify
Trichosanthes root
Trichosanthes root contains bioactive compounds that exhibit anti-inflammatory, immunomodulatory, and potential antitumor properties through multiple cellular pathways.
Trichosanthes root contains bioactive compounds that exhibit anti-inflammatory, immunomodulatory, and potential antitumor properties through multiple cellular pathways. Used for Cancer (various types, traditional use in Chinese medicine), Inflammatory conditions.
At a glance
| Generic name | Trichosanthes root |
|---|---|
| Sponsor | China Medical University Hospital |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Trichosanthes root (from the plant Trichosanthes kirilowii) is a traditional Chinese medicine ingredient containing proteins, polysaccharides, and other phytochemicals that modulate immune function and inflammatory responses. Preclinical studies suggest it may inhibit tumor cell proliferation and induce apoptosis, though the exact molecular mechanisms remain incompletely characterized in clinical settings.
Approved indications
- Cancer (various types, traditional use in Chinese medicine)
- Inflammatory conditions
Common side effects
- Gastrointestinal disturbance
- Allergic reactions
Key clinical trials
- Effectiveness of Joins® for Managing Lumbar Facetogenic Pain (NA)
- The Effects of Trichosanthes Root on Blood Sugar in Patients With Diabetes Mellitus (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trichosanthes root CI brief — competitive landscape report
- Trichosanthes root updates RSS · CI watch RSS
- China Medical University Hospital portfolio CI